Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients.
Breast cancer
Early stage
Lymph node
Recurrence
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
03
07
2023
accepted:
10
08
2023
medline:
27
10
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
We evaluated the outcomes, and risk factors for recurrence in patients with early stage node-negative breast cancer in this study. Retrospective data analysis was done on patient treatment records from 1988 to 2018. The patient's demographic, clinical, pathological, and therapeutic characteristics were noted. To evaluate survival analysis and predictors of recurrence, we employed Kaplan-Meier analysis with the log-rank test. A total of 357 patients in all were enrolled in the research. At the time of diagnosis, the median age was 50 (with a range of 18-81). A total of 85.5% of patients had undergone a lumpectomy, while 14.5% had a mastectomy. 78.7% of patients had sentinel lymph node biopsy, and 21.3% had axillary lymph node dissection. In addition, the patients received adjuvant radiotherapy (88.7%), adjuvant endocrine therapy (82.1%), and adjuvant chemotherapy (48.5%). Recurrence of the tumor occurred in 31 (8.7%) patients (local recurrence 45.2% and metastatic disease 54.8%). Ten- and twenty-year recurrence-free survival rates were 92% and 77%. 19 (5.3%) patients had also developed contralateral breast cancer. Ten-year survival rates were 91.6%, and 20-year survival rates were 76.6%, respectively. Aged over 65 years (p = 0.004), necrosis (p = 0.002), mitosis (p = 0.003), and nuclear pleomorphism (p = 0.049) were found as statistically significant factors for recurrence in univariate analysis. In the ROC analysis, the largest size of the tumor (over 1.45 cm, p = 0.07) remained outside the statistical significance limit in terms of recurrence. Thirty-year outcomes in individuals with early stage, node-negative breast cancer were shown in this study. We found that the recurrence ratios between 10 and 20 years were more frequent than the first 10 years during the follow-up. Despite the small number of patients who experienced a recurrence, we demonstrated that, in univariate analysis, being older than 65 and having some pathological characteristics (nuclear pleomorphism, mitosis, and necrosis) were statistically significant factors for disease recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
We evaluated the outcomes, and risk factors for recurrence in patients with early stage node-negative breast cancer in this study.
METHOD
METHODS
Retrospective data analysis was done on patient treatment records from 1988 to 2018. The patient's demographic, clinical, pathological, and therapeutic characteristics were noted. To evaluate survival analysis and predictors of recurrence, we employed Kaplan-Meier analysis with the log-rank test.
RESULTS
RESULTS
A total of 357 patients in all were enrolled in the research. At the time of diagnosis, the median age was 50 (with a range of 18-81). A total of 85.5% of patients had undergone a lumpectomy, while 14.5% had a mastectomy. 78.7% of patients had sentinel lymph node biopsy, and 21.3% had axillary lymph node dissection. In addition, the patients received adjuvant radiotherapy (88.7%), adjuvant endocrine therapy (82.1%), and adjuvant chemotherapy (48.5%). Recurrence of the tumor occurred in 31 (8.7%) patients (local recurrence 45.2% and metastatic disease 54.8%). Ten- and twenty-year recurrence-free survival rates were 92% and 77%. 19 (5.3%) patients had also developed contralateral breast cancer. Ten-year survival rates were 91.6%, and 20-year survival rates were 76.6%, respectively. Aged over 65 years (p = 0.004), necrosis (p = 0.002), mitosis (p = 0.003), and nuclear pleomorphism (p = 0.049) were found as statistically significant factors for recurrence in univariate analysis. In the ROC analysis, the largest size of the tumor (over 1.45 cm, p = 0.07) remained outside the statistical significance limit in terms of recurrence.
CONCLUSIONS
CONCLUSIONS
Thirty-year outcomes in individuals with early stage, node-negative breast cancer were shown in this study. We found that the recurrence ratios between 10 and 20 years were more frequent than the first 10 years during the follow-up. Despite the small number of patients who experienced a recurrence, we demonstrated that, in univariate analysis, being older than 65 and having some pathological characteristics (nuclear pleomorphism, mitosis, and necrosis) were statistically significant factors for disease recurrence.
Identifiants
pubmed: 37594533
doi: 10.1007/s00432-023-05276-y
pii: 10.1007/s00432-023-05276-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14833-14841Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29(29):3885–3891
doi: 10.1200/JCO.2011.36.1105
pubmed: 21900114
pmcid: 3189090
Billena C, Wilgucki M, Flynn J, Modlin L, Tadros A, Razavi P, Braunstein LZ, Gillespie E, Cahlon O, McCormick B, Zhang Z, Morrow M, Powell S, Khan AJ (2021) 10-year breast cancer outcomes in women </=35 years of age. Int J Radiat Oncol Biol Phys 109(4):1007–1018
doi: 10.1016/j.ijrobp.2020.10.022
pubmed: 33371964
Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Bellon JR, Wong JS, Punglia RS, MacDonald SM, Harris JR (2017) Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat 161(1):173–179
doi: 10.1007/s10549-016-4031-5
pubmed: 27807809
Eaker S, Dickman PW, Bergkvist L, Holmberg L, Uppsala G, Cancer OB (2006) Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med 3(3):e25
doi: 10.1371/journal.pmed.0030025
pubmed: 16409108
pmcid: 1326256
Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P (2013) Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 139(5):853–860
doi: 10.1007/s00432-013-1388-2
pubmed: 23411686
pmcid: 3625404
Gandhi H, Maru A, Shah N, Mansuriya RK, Rathod G, Parmar P (2023) Correlation of Robinson’s cytological grading with Elston and Ellis’ Nottingham modification of bloom Richardson score of histopathology for breast carcinoma. Maedica (bucur) 18(1):55–60
pubmed: 37266482
Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC (2019) Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol 5(10):1473–1478
doi: 10.1001/jamaoncol.2019.1838
pubmed: 31369045
pmcid: 6681568
Giannakeas V, Lim DW, Narod SA (2021) The risk of contralateral breast cancer: a SEER-based analysis. Br J Cancer 125(4):601–610
doi: 10.1038/s41416-021-01417-7
pubmed: 34040177
pmcid: 8368197
Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (basel) 13(17):4287
doi: 10.3390/cancers13174287
pubmed: 34503097
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF, Ebctcg. (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846
doi: 10.1056/NEJMoa1701830
pubmed: 29117498
pmcid: 5734609
Pedersen RN, Esen BO, Mellemkjaer L, Christiansen P, Ejlertsen B, Lash TL, Norgaard M, Cronin-Fenton D (2022) The incidence of breast cancer recurrence 10–32 years after primary diagnosis. J Natl Cancer Inst 114(3):391–399
doi: 10.1093/jnci/djab202
pubmed: 34747484
Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26(19):3153–3158
doi: 10.1200/JCO.2007.15.5986
pubmed: 18490649
Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM (2010) Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899–2908
doi: 10.1245/s10434-010-1089-x
pubmed: 20443145
pmcid: 4324592
Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48
doi: 10.3322/caac.21763
pubmed: 36633525
Soliman H, Shah V, Srkalovic G, Mahtani R, Levine E, Mavromatis B, Srinivasiah J, Kassar M, Gabordi R, Qamar R, Untch S, Kling HM, Treece T, Audeh W (2020) MammaPrint guides treatment decisions in breast cancer: results of the IMPACt trial. BMC Cancer 20(1):81
doi: 10.1186/s12885-020-6534-z
pubmed: 32005181
pmcid: 6995096
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
pubmed: 33538338
Syed YY (2020) Oncotype DX breast recurrence score((R)): a review of its use in early-stage breast cancer. Mol Diagn Ther 24(5):621–632
doi: 10.1007/s40291-020-00482-7
pubmed: 32613290
van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ET, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307(6):590–597
pubmed: 22318280
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32(20):2142–2150
doi: 10.1200/JCO.2013.53.1608
pubmed: 24888816
pmcid: 4076026
Zemni I, Ghalleb M, Jbir I, Slimane M, Ben Hassouna J, Ben Dhieb T, Bouzaiene H, Rahal K (2017) Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients. World J Surg Oncol 15(1):206
doi: 10.1186/s12957-017-1272-7
pubmed: 29169398
pmcid: 5701354